Long-Terms Responders in Metastatic Lung Cancer: Better Understanding for Better Management (Lungevity Study)

The goal of this observational study is to identify and describe the clinical characteristics, health status, socio-economic impacts and quality of life of patients alive for three years after diagnosis of metastatic Lung cancer and no longer receiving cytotoxic chemotherapy. The main question is to identify the needs of these patients in terms of health status (impact of cancer treatments, incidence of new diseases, cardiovascular, diabetes, second cancers), socio-economic aspects, quality of life and return to employment. Participants will be asked to answer quality of life questionnaires at the time of inclusion and 6 and 12 months after inclusion and then, every year up to 5 years in this study. They will be followed regularly, in consultations, according to the usual practices of the physicians in each participating center.

NCT Number	NCT07243132
Lead Sponsor	GFPC Investigation
Conditions	Metastatic Lung Cancer, Metastatic NSCLC, Metastatic Small Cell Lung Cancer
Enrollment	1,000 participants
Start Date	2025-07-02
Primary Completion	2031-01-31 (estimated)
Study Completion	2031-01-31 (estimated)
Updated on ClinicalTrials.gov	2026-04-27